CoChat
Sign Up
Cited by 441

The DOI matches its Crossref record.

Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene

Wo Tsui, Hing, Siminovitch, Katherine A., de Souza, Loretta, Tsui, Florence W.L.·1993·Nature Genetics
DOI 10.1038/ng0693-124
Open this paper in CoChat — free account

Abstract

Mice with the recessive motheaten (me) or the allelic viable motheaten (mev) mutations express a severe autoimmune and immunodeficiency syndrome. We have shown that the basic defect in these mice involves lesions in the gene which encodes haematopoietic cell phosphatase (HCP). These mice thus provide excellent models for investigating the roles of phosphatases in haematopoiesis and the nature of the genetic and cellular events linking impaired haematopoiesis to severe immunodeficiency and expression of systemic autoimmunity.

Overview

Integrity signals

Registry

Crossref · 10.1038/ng0693-124

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 31

  1. Green, M.C., Shultz, L.D. Motheaten, an immunodeficient mutant of the mouse. J. Hered. 66, 250–258 (1975). · DOI
  2. Sidman, C.L., Shultz, L.D. & Unanue, E.R. The mouse mutant “motheaten”. I. Development of lymphocyte populations. J. Immunol. 121, 2392–2398 (1978). · DOI
  3. Shultz, L.D., Coman, D.R., Bailey, C.L., Beamer, W.G. & Sidman, C.L. “Viable Motheaten”, a new allele at the Motheaten locus. I. Pathology. Am. J. Pathol. 116, 179–192 (1984).
  4. Greiner, D.L. et al. Defective lymphopoiesis in the bone marrow of motheaten (me/me) and viable motheaten (mev/mev) mutant mice. I. Analysis of the development of prothymocytes, B lineage cells and terminal deoxynucleotidyl-transferase-positive cells. J. exp. Med. 164, 1129–1144 (1986). · DOI
  5. Davidson, W.F., Morse, H.C., Sharrow, S.D. & Chused, T.M. Phenotypic and functional effects of the motheaten gene on murine B and T lymphocytes. J. Immunol. 122, 884–891 (1979). · DOI
  6. Sidman, C.L., Shultz, L.D. & Unanue, E.R. The mouse mutant “motheaten”. II. Functional studies of the immune system. J. Immunol. 121, 2399–2404 (1978). · DOI
  7. Sidman, C.L., Shultz, L.D., Hardy, R., Hayakawa, K. & Herzenberg, L.A. Production of immunoglobulin isotypes by Ly–1+ B cells in viable motheaten and normal mice. Science 232, 1423–1425 (1986). · DOI
  8. Clark, E.A., Shultz, L.D. & Pollack, S.B. Mutations in mice that influence natural killer (NK) cell activity. Immunogenet. 12, 601–613 (1981). · DOI
  9. Koo, G.C., Manyak, C.L., Dasch, J., Ellingsworth, L. & Shultz, L.D. Suppressive effects of monocytic cells and TGF–beta on NK differentiation in autoimmune viable motheaten mutant mice. J. Immunol. 147, 1194–1200 (1991). · DOI
  10. McCoy, K.L., Neilson, K. & Clagett, J. Spontaneous production of colony-stimulating activity by splenic MAC–1 antigen-positive cells from autoimmune motheaten mice. J. Immunol. 132, 272–276 (1984). · DOI
  11. Hayashi, S.I., Witte, P.L., Shultz, L.D. & Kincade, P.W. Lymphohemopoiesis in culture is prevented by interaction with adherent bone marrow cells from mutant viable motheaten mice. J. Immunol. 140, 2139–2147 (1988). · DOI
  12. Yi, T., Cleveland, J.L. & Ihle, J.N. Protein tyrosine phosphatase containing SH2 domains. Characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12–p13. Molec. cell Biol. 12, 836–846 (1992). · DOI · Paper page
  13. Plutzky, J. et al. Chromosomal localization of an SH2-containing tyrosine phosphatase (PTPN6). Genomics 13, 869–872 (1992). · DOI
  14. Shen, S-H., Bastien, L., Posner, R.I. & Chretien, P. A protein-tyrosine phosphatase with sequence similarity to the SH2 domain of the protein-tyrosine kinases. Nature 352, 736–739 (1991). · DOI · Paper page
  15. Matthews, R.J., Bowne, D.B., Flores, E. & Thomas, M.L. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-, glutamic acid-, serine-, and threonine-rich sequences. Molec. cell Biol. 12, 2396–2405 (1992). · DOI
  16. Plutzky, J., Neel, B.G. & Rosenberg, R.D. Isolation of an src homology 2-containing tyrosine phosphatase. Proc. natn. Acad. Sci. U.S.A. 89, 1123–1127 (1992). · DOI
  17. Sidman, C.L., Marshall, J.D. & Allen, R.D. Murine “viable motheaten” mutation reveals a gene critical to the development of both B and T lymphocytes. Proc. natn. Acad. Sci. U.S.A. 86, 6279–6282 (1989). · DOI
  18. Mount, S.M. A catalogue of splice junction sequences. Nucl. Acid Res. 10, 459–472 (1982). · DOI
  19. Weatherall, D.J. The New Genetics and Clinical Practice 2nd edn 80–81 (University Press, Oxford, 1985).
  20. Yi, T., Gilbert, D.J., Jenkins, N.A., Copeland, N.G. & Ihle, J.N. Assignment of a novel protein tyrosine phosphatase gene (Hcph). Genomics 14, 793–795 (1992). · DOI
  21. Hunter, T. Protein-tyrosine phosphatase: the other side of the coin. Cell 58, 1013–1016 (1989). · DOI
  22. Yarden, Y. & Ullrich, A. Growth factor receptor tyrosine kinases. Ann. Rev. Biochem. 57, 443–478 (1988). · DOI
  23. Pawson, T. & Bernstein, A. Receptor tyrosine kinases: genetic evidence for their role in Drosophila and mouse development. Trends Genet. 6, 350–356 (1990). · DOI
  24. Cool, D.E., Tonks, N.K., Fischer, E.H. & Krebs, E.G. Expression of a human T-cell protein-tyrosine-phosphatase in baby hamster kidney cells. Proc. natn. Acad. Sci. U.S.A. 87, 7280–7284 (1990). · DOI
  25. Ramponi, G., Ruggiero, M. & Rauyei, G. Overexpression of a synthetic phospho-tyrosine protein phosphatase gene inhibits normal and transformed cell growth. Int. J. Cancer 51, 652–656 (1992). · DOI
  26. Brown-Shimer, S., Johnson, K.A., Hill, D.E. & Bruskin, A.M. Effect of protein tyrosine phosphatase 1B expression on transformation by the human neu oncogene. Cancer Res. 52, 478–482 (1992).
  27. Koch, C.A., Anderson, D., Moran, M.F., Ellis, C. & Pawson, T. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252, 668–674 (1991). · DOI
  28. Chirgwin, J.M., Przybyla, A.E., MacDonald, R.J. & Rutter, W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294–5299 (1979). · DOI
  29. Chomczynski, P. & Sacchi, N.A. Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162, 156–159 (1987). · DOI
  30. Sambrook, J., Fritsch, E.F. & Maniatis, T. in Molecular Cloning: A Laboratory Manual 2nd edn (Cold Spring Harbor Laboratory Press, New York, 1989).
  31. Winship, P.R. An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide. Nucl. Acid Res. 17, 1266 (1989). · DOI

Cited by

Sorted by citations

See all 441

Metadata

Authors
Wo Tsui, H., Siminovitch, K. A., de Souza, L., & Tsui, F. W. L.
Venue
Nature Genetics
Publisher
Springer Science and Business Media LLC
Published
1993-06
Volume
4
Issue
2
Pages
124-129
ISSN
  • 1061-4036
  • 1546-1718
DOI
10.1038/ng0693-124
Cited by
441
References
0
Language
en
Licence
www.springer.com/tdm (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review